Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2006

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Cancer of the Bile DuctGallbladder Cancer
Interventions
DRUG

GM-CT-01

GM-CT-01 at 280 mg/m2 given IV for 4 consecutive days in 28 days cycle until disease progression

DRUG

5-Fluorouracil

5-FU given IV by infusion for 30, at 600 mg/m2 in combination with GM-CT-01 for 4 consecutive days in 28 days cycle until disease progression

Trial Locations (3)

48109

University of Michigan, Comprehensive Cancer Center, Ann Arbor

02118

Boston Medical Center, Boston

45267-0501

Barrett Cancer Center, Cincinnati

Sponsors
All Listed Sponsors
lead

Galectin Therapeutics Inc.

INDUSTRY